The weekly litigation news digest is live. Subscribe now

Grnenthal competitive analysis

Loading summary...

Explore Grnenthal's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
Jul 13, 2022Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt2
Nov 17, 2021Process For The Preparation Of (1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol3
Apr 14, 2021Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol7
Jul 22, 2020(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful Inflammations4
Apr 22, 2020Aqueous Pharmaceutical Formulation Of Tapentadol For Oral Administration1
Oct 2, 2019Tapentadol For Treating Pain Associated With Trigeminal Neuralgia1
Oct 31, 2018Tapentadol For Preventing Chronification Of Pain3
Mar 22, 2017Break-Resistant Delayed-Release Forms Of Administration1

Latest PTAB cases involving Grnenthal

Discover the latest PTAB cases involving Grnenthal, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 18, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Grnenthal

PGR2018-00062Apr 18, 2018GRNENTHALANTICEP BIOVENTURES IIFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Grnenthal with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GRNENTHAL - 221 -
GENERICS UK214 - - -
G L PHARMA9 - - -
HAMM & WITTKOPP112 - - -